JP2021511830A5 - - Google Patents
Info
- Publication number
- JP2021511830A5 JP2021511830A5 JP2020561607A JP2020561607A JP2021511830A5 JP 2021511830 A5 JP2021511830 A5 JP 2021511830A5 JP 2020561607 A JP2020561607 A JP 2020561607A JP 2020561607 A JP2020561607 A JP 2020561607A JP 2021511830 A5 JP2021511830 A5 JP 2021511830A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- tyrosine
- isolated
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204313A JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| US62/622,468 | 2018-01-26 | ||
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204313A Division JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511830A JP2021511830A (ja) | 2021-05-13 |
| JP2021511830A5 true JP2021511830A5 (https=) | 2022-02-01 |
| JP7399880B2 JP7399880B2 (ja) | 2023-12-18 |
Family
ID=65520379
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2023204313A Pending JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204313A Pending JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (https=) |
| EP (1) | EP3743441A1 (https=) |
| JP (3) | JP7399880B2 (https=) |
| KR (2) | KR20250008975A (https=) |
| CN (2) | CN111788221B (https=) |
| AU (2) | AU2019212638B2 (https=) |
| BR (1) | BR112020015006A2 (https=) |
| CA (1) | CA3089602A1 (https=) |
| CO (1) | CO2020010269A2 (https=) |
| IL (2) | IL276286B2 (https=) |
| MX (2) | MX2020007882A (https=) |
| MY (1) | MY203898A (https=) |
| PH (1) | PH12020551134A1 (https=) |
| SG (1) | SG11202006905YA (https=) |
| TW (1) | TW201940512A (https=) |
| WO (1) | WO2019147973A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| WO2021016571A2 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
| CA3156803A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| CN120590527A (zh) * | 2020-05-11 | 2025-09-05 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| KR20230093483A (ko) * | 2020-10-29 | 2023-06-27 | 포르미콘 아게 | Ace2 융합 단백질 및 이의 용도 |
| EP4347640A1 (en) | 2021-05-27 | 2024-04-10 | Sanofi | Fc variant with enhanced affinity to fc receptors and improved thermal stability |
| AU2022329459A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023064841A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | Antibodies for use against sars-cov-2 |
| KR20250017240A (ko) | 2022-05-27 | 2025-02-04 | 사노피 | FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자 |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| EP4630455A1 (en) | 2022-12-05 | 2025-10-15 | Sanofi | Transferrin receptor binding proteins |
| TW202535925A (zh) | 2023-10-25 | 2025-09-16 | 比利時商艾伯霖克斯公司 | 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體 |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| WO2026022712A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| PL209392B1 (pl) * | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2010068722A1 (en) * | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| DK2516468T3 (en) * | 2009-12-23 | 2016-05-23 | Synimmune Gmbh | ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| DK3215528T3 (da) * | 2014-11-06 | 2019-10-07 | Hoffmann La Roche | Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder |
| JP6787888B2 (ja) * | 2014-11-10 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｉｌ−１ベータ抗体及び使用方法 |
| HRP20260151T1 (hr) * | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
-
2019
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 CN CN201980015900.4A patent/CN111788221B/zh active Active
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
-
2020
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
- 2025-10-24 JP JP2025179195A patent/JP2026021377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511830A5 (https=) | ||
| JP2024026255A5 (https=) | ||
| IL276286B1 (en) | FC variants with improved binding to FCRN and extended half-life | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| TWI320788B (en) | Method for the purification of antibodies | |
| US11945839B2 (en) | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography | |
| JPWO2020116560A1 (ja) | 抗体のＦｃ領域改変体 | |
| CN111320693B (zh) | 抗EphA4抗体 | |
| JP2020508968A (ja) | プロテインｌを用いたタンパク質精製 | |
| TW202233694A (zh) | 雙特異性抗體 | |
| JP7245373B2 (ja) | 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法 | |
| JPWO2015050153A1 (ja) | 免疫グロブリンＧ（ＩｇＧ）のＦｃ部分を有するタンパク質に対するアフィニティを有する複数のドメイン間をリンカーで結合させて成るタンパク質 | |
| TW202204423A (zh) | 用於產生和純化多價免疫球蛋白單可變域的方法 | |
| CN110959012A (zh) | 工程化表面电荷用于产生双特异性抗体的方法 | |
| JP2019030231A (ja) | 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 | |
| JPWO2007063825A1 (ja) | Ｃｄ１６６に対するモノクローナル抗体およびその産生方法 | |
| JP2024522092A5 (https=) | ||
| JP7796415B2 (ja) | エリスロポエチンポリペプチドを含む融合タンパク質 | |
| JP2015019615A (ja) | プロテインｇの細胞膜外ドメイン変異体の新規な改変型タンパク質 | |
| JP7839108B2 (ja) | 筋萎縮性側索硬化症の治療用医薬組成物 | |
| NZ767453B2 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
| CN120225567A (zh) | 与酸性神经鞘磷脂酶蛋白特异性结合的抗体 | |
| HK40085483B (zh) | 异二聚体fc多肽 |